Although these days the race to develop a COVID-19 vaccine is taking centre stage in the current biosciences environment, oncology still plays a key role as being the next largest area for investment activity. Before COVID-19 struck, oncology represented nearly half of the buy-side transactions for the large pharma dealmakers, and topped US venture capital funding by disease area. Most oncology therapy deals are characterised by M&A (70%) whereas licensing makes up much less of the total (27%).
Our Q4 2020 report provides an in-depth analysis of this dynamic investment environment along with the latest developments in the field of immuno-oncology therapeutics.
Table of contents:
Deal Landscape
M&A Deals
Licensing Deals
Venture Capital
Key Immuno-Oncology Therapies
CAR-T
CRISPR
Neoantigen Vaccines
Checkpoint Inhibitors
Combination Therapies
Biomarkers
Companion Diagnostics
Next Generation Sequencing
Clinical Trials
You can download our report from here:
For further details and enquiries please contact Anthony Vago at anthony.vago@friday.capital.